JP2013504623A5 - - Google Patents

Download PDF

Info

Publication number
JP2013504623A5
JP2013504623A5 JP2012529823A JP2012529823A JP2013504623A5 JP 2013504623 A5 JP2013504623 A5 JP 2013504623A5 JP 2012529823 A JP2012529823 A JP 2012529823A JP 2012529823 A JP2012529823 A JP 2012529823A JP 2013504623 A5 JP2013504623 A5 JP 2013504623A5
Authority
JP
Japan
Prior art keywords
yeast
based immunotherapy
agent
subject
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012529823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504623A (ja
JP5913103B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/048699 external-priority patent/WO2011032119A1/en
Publication of JP2013504623A publication Critical patent/JP2013504623A/ja
Publication of JP2013504623A5 publication Critical patent/JP2013504623A5/ja
Application granted granted Critical
Publication of JP5913103B2 publication Critical patent/JP5913103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012529823A 2009-09-14 2010-09-14 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 Active JP5913103B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24235509P 2009-09-14 2009-09-14
US24235309P 2009-09-14 2009-09-14
US61/242,355 2009-09-14
US61/242,353 2009-09-14
US28856809P 2009-12-21 2009-12-21
US61/288,568 2009-12-21
PCT/US2010/048699 WO2011032119A1 (en) 2009-09-14 2010-09-14 Modulation of yeast-based immunotherapy products and responses

Publications (3)

Publication Number Publication Date
JP2013504623A JP2013504623A (ja) 2013-02-07
JP2013504623A5 true JP2013504623A5 (https=) 2013-11-07
JP5913103B2 JP5913103B2 (ja) 2016-04-27

Family

ID=43034390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529823A Active JP5913103B2 (ja) 2009-09-14 2010-09-14 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法

Country Status (6)

Country Link
US (3) US8911722B2 (https=)
EP (1) EP2477647B1 (https=)
JP (1) JP5913103B2 (https=)
AU (1) AU2010291985B2 (https=)
CA (1) CA2774326C (https=)
WO (1) WO2011032119A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
MX350661B (es) 2011-03-17 2017-09-13 Us Health Composiciones inmunoterapeuticas de levadura-brachyuri.
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2929351B1 (en) * 2012-12-10 2019-10-09 The University of Queensland Cell-free biofragment compositions and related systems, devices, and methods
AU2014265873B2 (en) 2013-03-19 2019-01-17 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EP3308800B1 (en) * 2015-06-10 2021-08-25 The University of Tokyo Adjuvant for vaccines, vaccine, and immunity induction method
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
US20180250369A1 (en) * 2015-09-11 2018-09-06 Ventria Bioscience, Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
CA3152190A1 (en) * 2019-08-26 2021-03-04 The Brigham & Women's Hospital, Inc. Compositions and uses for engineered therapeutic microbes and associated receptors
EP4489774A4 (en) * 2022-03-08 2026-04-29 Immunitybio Inc YEAST-BASED VACCINE INJECTED INTRATUMORALLY

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
JPH09502086A (ja) 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2005086835A2 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US20050239134A1 (en) 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
SG163572A1 (en) 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
JP2009510093A (ja) 2005-09-28 2009-03-12 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆアンタゴニストならびにその使用方法
PL1940465T3 (pl) 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
WO2007114861A2 (en) 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
BRPI0619118A2 (pt) 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
US7736642B2 (en) 2006-02-02 2010-06-15 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
MX2008013993A (es) 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
EP2046835B1 (en) * 2006-08-11 2011-10-26 Schering Corporation Antibodies to il-17a
WO2008025032A1 (en) 2006-08-25 2008-02-28 Zymogenetics, Inc. Soluble il-27 receptor
WO2008025033A2 (en) 2006-08-25 2008-02-28 Zymogenetics, Inc. Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
US20100150862A1 (en) 2006-12-07 2010-06-17 Schering Corporation Methods of modulating maternal-fetal tolerance
WO2008071685A1 (en) 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
US8211420B2 (en) 2006-12-21 2012-07-03 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009047360A1 (en) 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2096438A1 (en) * 2008-02-28 2009-09-02 Martin Thurnher Methods for prognosing the status of patients
WO2009132821A1 (en) 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
US8178097B2 (en) 2008-05-23 2012-05-15 Wyeth Llc Methods of treatment utilizing binding proteins of the interleukin-21 receptor
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
EP2547792A4 (en) 2010-03-14 2013-11-27 Globeimmune Inc PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection

Similar Documents

Publication Publication Date Title
JP2013504623A5 (https=)
Hussain et al. Similar but different: virtual memory CD8 T cells as a memory‐like cell population
Dwivedi et al. Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions
Wesa et al. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro
Jost et al. Changes in cytokine levels and NK cell activation associated with influenza
Movita et al. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct
Zilliox et al. Gene expression changes in peripheral blood mononuclear cells during measles virus infection
Leonardi et al. Akt-Fas to quell aberrant T cell differentiation and apoptosis in Covid-19
Wang et al. Increased frequencies of T helper type 17 cells in tuberculous pleural effusion
Tan et al. Deficiency of canonical wnt/β‐catenin signalling in hepatic dendritic cells triggers autoimmune hepatitis
Fujii et al. Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity
Moafi et al. Comparison of pro‐inflammatory cytokines of non‐healing and healing cutaneous leishmaniasis
Tong et al. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
Urban et al. Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses
Alam et al. CD25-targeted IL-2 signals promote improved outcomes of influenza infection and boost memory CD4 T cell formation
Lineburg et al. Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity
Prakash et al. Dendritic cells from aged subjects display enhanced inflammatory responses to Chlamydophila pneumoniae
Yang et al. Lung tissue–resident memory T cells optimize protection by IL-10 regulation of innate immunity
Fernandes et al. Paracoccidioides brasiliensis interferes on dendritic cells maturation by inhibiting PGE2 production
Griffin Are T cells helpful for COVID-19: the relationship between response and risk
Akilimali et al. Cryptococcosis-associated immune reconstitution inflammatory syndrome is associated with dysregulation of IL-7/IL-7 receptor signaling pathway in T cells and monocyte activation
Devalraju et al. Defective expansion and function of memory like natural killer cells in HIV+ individuals with latent tuberculosis infection
Chauvin et al. Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
Kim et al. Pathological and therapeutic roles of innate lymphoid cells in diverse diseases
CN106610423A (zh) 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法